Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance

• Autori principali: Marija Križić (Autore), Marina Popović (Autore), Tajana Silovski (Autore), Dorotea Grbin (Autore), Natalija Dedić Plavetić (Autore)
• Natura: Libro
• Pubblicazione: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Background and Objective Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab combined with taxane-based chemotherapy (Cht) has been the standard first-line treatment for HER2-positive metastatic breast cancer (mBC) for years, due to the impressive r...